Judge Engelmayer’s Decision: Breaking Promises Allegation Stands Strong
In a recent legal development, Abbott Laboratories faces a setback as a judge refuses to dismiss a lawsuit filed by Joanne Noriega, a grandmother from New York City. The lawsuit revolves around allegations that Abbott misled consumers, specifically breaking promises regarding the effectiveness of its PediaSure Grow & Gain nutrition drinks, claiming clinical proof of enhancing children’s height.
Unravelling the Deception in Abbott’s Marketing
U.S. District Judge Paul Engelmayer, presiding in Manhattan, has deemed Noriega’s complaint substantial, citing evidence-backed reasons that challenge Abbott’s marketing claims. Noriega, representing New Yorkers allegedly misled, emphasized three studies funded by Abbott that found no link between PediaSure and height growth.
Strengthening the Case
Judge Engelmayer pointed out the significance of these contradicting studies, reinforcing the breaking promises allegation in the complaint. Abbott and its legal representatives are yet to respond to the judge’s decision.
A Grandmother’s Perspective
Noriega, a resident of the Bronx, shared her experience of purchasing PediaSure Grow & Gain drinks for her 8-year-old grandson in the hope of promoting height growth. Despite a year of consistent consumption, Noriega observed no improvement in height and, notably, an increase in weight, leading her to stop buying the drinks.
Legal Implications
James Denlea, Noriega’s lawyer, expressed satisfaction with the judge’s decision, seeing it as an opportunity to gather more evidence during the discovery process. Denlea argued that Abbott possessed studies contradicting their growth claims, revealing a pattern of breaking promises in their marketing practices.
Seeking Damages: Breaking Promises in the Consumer Realm
The lawsuit, seeking unspecified damages, represents New Yorkers who allegedly fell victim to deceptive marketing, purchasing or overpaying for PediaSure based on promises that Abbott failed to fulfil. Abbott has consistently stated that PediaSure targets children aged 2 to 13, assisting them in moving out of at-risk weight-for-height percentiles (5th-25th percentiles) within eight weeks.
PediaSure’s Role in Pediatric Nutrition
PediaSure is part of Abbott Laboratories’ pediatric nutritional segment, alongside Pedialyte and Similac. The case, officially titled Noriega v Abbott Laboratories, is currently under the jurisdiction of the U.S. District Court, Southern District of New York, with case number 23-04014. The breaking promises allegation brings to light the intricate intersection of corporate marketing and consumer expectations in the realm of pediatric nutrition.
Read more about it here.